Glaxosmithkline Intellectual Property Development Limited

David Barros Aguirre

Robert H Bates

Julia Castro Pichel

Lluis Ballell Pages

Kevin Pethe

Alfonso Mendoza Losana

Jorge Esquivias Provencio

Ruben Gonzalez Del Rio

Santiago Ramón García

Santiago RAMÓN GARCÍA

The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.

Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection

The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.

Antituberculosis agent

Growing community of inventors

Madrid, Spain

David Barros Aguirre